Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$820M |
| 2 |
Palo Alto Networks
PANW
|
+$358M |
| 3 |
Visa
V
|
+$355M |
| 4 |
CELG
Celgene Corp
CELG
|
+$339M |
| 5 |
Citigroup
C
|
+$325M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$722M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$356M |
| 3 |
Alibaba
BABA
|
+$345M |
| 4 |
EOG Resources
EOG
|
+$344M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.08% |
| 2 | Consumer Discretionary | 17.25% |
| 3 | Communication Services | 14.3% |
| 4 | Technology | 13.13% |
| 5 | Financials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Acadia Pharmaceuticals
ACAD
$4.55B
| $36.3M | 0.04% |
1,097,364
-1,423,960
| -56% | -$59.2M |
|
|
SPN
352
DELISTED
Superior Energy Services, Inc.
SPN
| $36.2M | 0.04% |
286,893
-64,806
| -18% | -$10.6M |
|
353
Darling Ingredients
DAR
$9.69B
| $36M | 0.04% |
3,201,739
+843,839
| +36% | +$10.8M |
|
354
BOK Financial
BOKF
$8.57B
| $35.9M | 0.04% |
554,762
+106,195
| +24% | +$6.91M |
|
|
DYAX
355
DELISTED
DYAX CORPORATION
DYAX
| $35.5M | 0.04% |
1,859,297
-435,068
| -19% | -$10.4M |
|
356
GE Aerospace
GE
$368B
| $35.3M | 0.04% |
+292,038
| New | +$35.8M |
|
|
CYT
357
DELISTED
CYTEC INDS INC
CYT
| $35.2M | 0.04% |
476,481
-383,311
| -45% | -$26.7M |
|
|
PETX
358
DELISTED
Aratana Therapeutics, Inc.
PETX
| $35.1M | 0.04% |
4,146,200
+714,413
| +21% | +$12.1M |
|
359
Zurn Elkay Water Solutions
ZWS
$8.31B
| $34.9M | 0.04% |
4,261,071
-246,739
| -5% | -$2.46M |
|
360
Flotek Industries
FTK
$847M
| $34.7M | 0.04% |
346,397
+4,815
| +1% | +$488K |
|
|
DYN
361
DELISTED
Dynegy, Inc.
DYN
| $34.7M | 0.04% |
1,677,930
-1,486,814
| -47% | -$37.7M |
|
362
Neurocrine Biosciences
NBIX
$18.7B
| $34.7M | 0.04% |
871,419
-4,312
| -0.5% | -$208K |
|
|
MDCO
363
DELISTED
Medicines Co
MDCO
| $34.1M | 0.04% |
899,315
+7,027
| +0.8% | +$247K |
|
364
Viatris
VTRS
$20.7B
| $34.1M | 0.03% |
846,954
-1,478,767
| -64% | -$82.4M |
|
365
Wendy's
WEN
$1.4B
| $33M | 0.03% |
3,819,118
+522,056
| +16% | +$5.06M |
|
366
NCR Voyix
VYX
$1.12B
| $33M | 0.03% |
2,363,128
-160
| -0% | -$2.67K |
|
367
Owens Corning
OC
$11.2B
| $32.7M | 0.03% |
780,024
+502,115
| +181% | +$22.1M |
|
368
MACOM Technology Solutions
MTSI
$19B
| $32.5M | 0.03% |
1,122,211
-2,975
| -0.3% | -$93.8K |
|
369
ManpowerGroup
MAN
$2.41B
| $32.5M | 0.03% |
397,139
-61,144
| -13% | -$5.45M |
|
370
Cencora
COR
$60.7B
| $32.2M | 0.03% |
339,205
+3,060
| +0.9% | +$321K |
|
371
CALL
Merck
MRK
$321B
| $32.1M | 0.03% |
+681,200
| New | +$36.2M |
|
372
Pembina Pipeline
PBA
$29.3B
| $31.9M | 0.03% |
1,327,528
+4,425
| +0.3% | +$124K |
|
373
Teladoc Health
TDOC
$1.19B
| $31.7M | 0.03% |
+1,423,322
| New | +$38.4M |
|
374
DaVita
DVA
$15.3B
| $31.7M | 0.03% |
438,111
+3,309
| +0.8% | +$257K |
|
375
Skyworks Solutions
SWKS
$9.4B
| $31.3M | 0.03% |
371,473
+367,268
| +8,734% | +$33.6M |
|
Similar funds
Jennison Associates's Q3 2015 Portfolio in Review
As of Q3 2015, Jennison Associates held 813 positions worth $97.6B, down 11% from $109B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jennison Associates's Q3 2015 filing shows 84 new, 272 increased, 353 reduced and 92 closed positions. Its largest new stake was Palo Alto Networks: 12,124,434 shares worth $348M. The largest sale was Gilead Sciences, an estimated $722M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q3 2015 buy was Palo Alto Networks: 12,124,434 shares worth $348M.
- Jennison Associates added most to Alphabet (Google) Class C in Q3 2015, an estimated $820M increase.
- Jennison Associates's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $722M.
- Jennison Associates fully exited KRAFT FOODS GROUP INC COM STK (VA) in Q3 2015, selling an estimated $144M.
- Jennison Associates's ten largest holdings make up 24% of its $97.6B portfolio in Q3 2015.
- Jennison Associates opened 84 new positions and closed 92 in Q3 2015.
- Jennison Associates's portfolio value fell 11% quarter-over-quarter to $97.6B.
Based on Jennison Associates's 13F filing for Q3 2015, filed 6 Nov 2015.